stockrow
Saturday 7 November 2026
Export STOK’s income statement to Excel — free account
Stoke Therapeutics, Inc.
STOK Healthcare Biotechnology
Stoke Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $184.4 million, up 404.5% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- −65.7%
- Free cash flow
- −114.9%
Quarter to September 2026, against a year earlier
26.54
0.47
+1.80%
Follow STOK
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
10.19 | 64.01 | 78.30 | 63.01 | |
P/FCF ratio |
41.85 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(61.72) | (33.89) | (38.17) | (28.35) | |
P/B ratio |
5.33 | 5.20 | 6.25 | 5.04 | |
Price to Tangible BV |
5.33 | 5.20 | 6.25 | 5.04 | |
EV/Sales |
8.65 | 53.30 | 67.68 | 51.69 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
34.99 | (11.65) | (10.49) | (6.93) | |
EV/FCF |
35.51 | (11.58) | (10.33) | (6.76) | |
Quick Ratio |
5.06 | 8.57 | 7.19 | 6.72 | |
Current Ratio |
5.28 | 8.99 | 7.69 | 7.24 | |
Net Debt/EBITDA |
4.62 | 6.44 | 4.48 | 4.13 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.53 | 0.08 | 0.07 | 0.07 | |
Operating CF/Net income |
0.53 | 1.21 | 0.92 | 0.85 | |
Capex/Depreciation |
1.59 | (4.77) | (22.20) | (27.41) | |
Research and Development Expense of Revenue |
2,973.97% | 636.91% | 530.84% | 531.59% | |
Selling, General and Administrative Expense of Revenue |
1,508.27% | 320.66% | 270.81% | 255.34% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
702.43% | 140.52% | 115.84% | 98.03% | |
Graham Net Nets |
0.13 | 0.16 | 0.13 | 0.17 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(0.32%) | (8.72%) | (10.30%) | (14.60%) | |
Free Cash Flow Yield |
2.39% | (7.19%) | (8.36%) | (12.14%) | |
Revenue per Share |
0.02 | 0.10 | 0.14 | 0.16 | |
Operating CF per Share |
(0.51) | (0.96) | (0.86) | (0.92) | |
Capex per Share |
0.00 | (0.01) | (0.03) | (0.04) | |
Free Cash Flow per Share |
(0.52) | (0.97) | (0.89) | (0.96) | |
Cash per Share |
4.81 | 5.45 | 4.44 | 4.67 | |
Shareholders Equity per Share |
5.95 | 6.26 | 5.23 | 5.16 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.95 | 6.26 | 5.23 | 5.16 | |
Free Cash Flow |
(30.69) | (60.93) | (58.56) | (65.54) | |
Working Capital |
247.83 | 325.88 | 280.61 | 305.44 | |
Capital Expenditures |
(0.23) | (0.35) | (1.98) | (2.85) | |
Net Current Asset Value |
239.72 | 318.28 | 274.12 | 300.31 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.17 | 0.06 | 0.21 | 0.25 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
5.14 | 3.37 | 5.17 | 10.46 | |
Average Payables |
3.72 | 4.51 | 4.55 | 4.95 | |
Average Assets |
344.99 | 425.08 | 389.24 | 383.48 | |
Average Common Equity |
290.74 | 372.48 | 340.25 | 330.35 |
Columns are period end dates · fundamentals updated 5 Nov 2026